Showing results (241-250 of 286) with videos related to
Sort By:
Pageof 29
The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.Nature|November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsRoy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.Journal for Immunotherapy of Cancer|May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysisAhmad A Tarhini, Ni Kang, Sandra J Lee, et al.Cancer|April 24, 2026
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignanciesTae Min Kim, Stephen K Williamson, Kyriakos P Papadopoulos, et al.Nature Medicine|September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trialGeorgina V Long, Nitya Nair, Daniel Marbach, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsKyung Hae Jung, Patricia LoRusso, Howard Burris, et al.European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumorsFlorentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.Pageof 29